TNF and rheumatoid arthritis: Tumor necrosis factor inhibitors (TNFi), such as infliximab (IFX), etanercept (ETN), and adalimumab (ADA), were the first biological disease-modifying antirheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) that had accumulated evidence of drug retention [1–5].